Thursday, March 03, 2022 12:11:33 PM
Invest,
The shareholders remedy is a shareholders derivative suit. But such a suit would have to be very, very fact specific in terms of proving "theft".
As I have discussed and cautioned previously, Management and the Board enjoy a strong legal presumption of correctness in their decisions, under the Business Judgment Rule.
This means that a Court would not take action unless the decisions made are unreasonable breaches of fiduciary duty/gross negligence, fraud, or self-dealing. Just because shareholders may think that the actions and decision-making of management, are stupid, delusional, tone-deaf, and not in the best interest of the shareholders, does not mean that a court would find such grounds sufficient to take action in the face of the business judgment rule.
The type of derivative actions that I am seriously looking at, are damages actions for what happened on 3/30/2020, against the lawyers for legal malpractice (Legal mal insurance), and the Board/Management for Breach of Fiduciary Duty (D&O Insurance). Any such recovery after costs and attorneys fees, would go to the company. A component of the latter action could seek equitable relief removing all Directors who were Directors at the time of the debacle.
The shareholders remedy is a shareholders derivative suit. But such a suit would have to be very, very fact specific in terms of proving "theft".
As I have discussed and cautioned previously, Management and the Board enjoy a strong legal presumption of correctness in their decisions, under the Business Judgment Rule.
This means that a Court would not take action unless the decisions made are unreasonable breaches of fiduciary duty/gross negligence, fraud, or self-dealing. Just because shareholders may think that the actions and decision-making of management, are stupid, delusional, tone-deaf, and not in the best interest of the shareholders, does not mean that a court would find such grounds sufficient to take action in the face of the business judgment rule.
The type of derivative actions that I am seriously looking at, are damages actions for what happened on 3/30/2020, against the lawyers for legal malpractice (Legal mal insurance), and the Board/Management for Breach of Fiduciary Duty (D&O Insurance). Any such recovery after costs and attorneys fees, would go to the company. A component of the latter action could seek equitable relief removing all Directors who were Directors at the time of the debacle.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
